On February 10, 2022, Metacrine, Inc. announced that Kristina Burow informed the Board of Directors (the “Board”) of her resignation as a member of the Board, the Audit Committee of the Board (the “Audit Committee”) and the Nominating and Corporate Governance Committee of the Board, effective immediately. Ms. Burow's resignation was not related to any disagreement with the Company over any of its operations, policies or practices. Effective immediately upon Ms. Burow's resignation, the Board decreased the authorized number of directors from 9 to 8 and the number of directors comprising Class II of the Board from 3 to 2. On February 10, 2022, effective immediately upon Ms. Burow's resignation, the Board appointed Jeffrey Jonker, a current director, to the Audit Committee to fill the vacancy resulting from Ms. Burow's resignation.